How to Help Your Patients Find Insulin Glargine in Stock: A Provider's Guide

Your patient calls the office in a panic: their pharmacy doesn't have Insulin Glargine, their insurance won't cover the alternative, and they're almost out. Sound familiar? In 2026, the disruption caused by Semglee's discontinuation and ongoing formulary transitions is generating these calls at unprecedented rates. This guide gives your practice a step-by-step playbook for helping patients resolve Insulin Glargine access issues quickly.

Step 1: Identify the Specific Problem

Not all Insulin Glargine access problems are the same. Before taking action, identify which category the patient falls into:

• Was on Semglee and has no current prescription: Needs a new Rx for an equivalent product (Lantus, Basaglar, Rezvoglar, generic glargine)
• Has a valid Rx but pharmacy is out of stock: Needs help finding a pharmacy with inventory
• Insurance won't cover the available product: Needs PA, formulary exception, or savings program guidance
• On Basaglar Tempo pen (being discontinued July 2026): Needs a new Rx for KwikPen before supply runs out

Step 2: Write the Right Prescription

For patients who were on Semglee or another discontinued product, write for one of these currently available U-100 Insulin Glargine products (all dose-equivalent, 1:1 conversion):

• Lantus (insulin glargine) 100 units/mL — vials or SoloStar pens (Sanofi)
• Basaglar (insulin glargine) 100 units/mL KwikPen (Eli Lilly)
• Rezvoglar (insulin glargine-aglr) 100 units/mL — FDA-interchangeable biosimilar (Eli Lilly)
• Generic Insulin Glargine 100 units/mL — available from Winthrop and others

When writing the prescription, consider specifying "may substitute interchangeable biosimilar" to give pharmacists maximum flexibility to dispense whichever product is on hand. Check your state's biosimilar substitution laws, as they vary.

Step 3: Navigate Insurance and Prior Authorization

If the patient's insurance isn't covering the available product due to formulary updates, here are strategies:

• Submit a PA immediately. For patients switching from Semglee, documentation that they have been stable on insulin glargine therapy is typically sufficient.
• Request urgency review. Insulin access qualifies as medically urgent in most plan policies — PA decisions should be rendered within 24–72 hours.
• Prescribe a bridge supply. Direct the patient to the Sanofi Valyou Savings Program ($35/month for Lantus) while the PA is processed. This program does not require insurance.
• Consider a formulary exception. If Lantus is on a non-preferred tier, you can request an exception citing the Semglee discontinuation as the clinical basis for needing the specific product.

Step 4: Help the Patient Locate a Pharmacy with Stock

Once the patient has a valid prescription for an available product, locating a pharmacy with stock is the next hurdle. Direct patients to medfinder.com, which calls pharmacies in the patient's area to find which ones can fill their specific Insulin Glargine prescription. This is far more efficient than patients calling pharmacies themselves.

Additional tips to share with patients:

• Try independent pharmacies — they often carry stock that major chains don't
• Ask the pharmacist about special ordering within 24–48 hours
• Check mail-order pharmacy availability through their insurance plan

Proactive Practice Management: Getting Ahead of the Problem

The most effective approach is to stay ahead of the transition before patients call in crisis. Consider these proactive steps:

1. Run an EHR report to identify all active patients with Semglee or Basaglar Tempo pen prescriptions.
2. Issue replacement Rx for Semglee patients, documenting the transition reason in the chart.
3. Contact Basaglar Tempo pen patients before July 27, 2026 to switch to KwikPen.
4. Create a standard response protocol for your staff when patients call about Insulin Glargine access — including the Sanofi Valyou savings info and medfinder referral.

medfinder for Providers

medfinder's provider tool allows your staff to quickly check Insulin Glargine availability at pharmacies near your patient's location, so you can route them directly to a pharmacy that can fill their prescription the same day. Learn more at medfinder.com/providers.

Also see our Insulin Glargine shortage update for providers and prescribers for detailed clinical guidance.